A substrate peptide for the FLT3 receptor tyrosine kinase

British Journal of Haematology

Volumn 144, Issue 1, 2009, Pages 127-130

  Böhmer, Frank D ^a,b   Uecker, Andrea ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Institute of Molecular Cell Biology   (Germany)

Author keywords

FLT3; Kinase assay; Kinase inhibitor; Peptide array; Peptide substrate

Indexed keywords

CD135 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; PROTEIN TYROSINE KINASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ASSAY; ENZYME SUBSTRATE; INSECT CELL; MYELOID LEUKEMIA; NONHUMAN; PEPTIDE ANALYSIS; PHOSPHORYLATION; PRIORITY JOURNAL;

ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; PEPTIDES; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; SEQUENCE ANALYSIS, PROTEIN;

EID: 57449108514     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07408.x     Document Type: Article

References (14)

1. Cheng, Y. Paz, K. (2008) Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs, 11, 46 56.
2. Choudhary, C., Müller-Tidow, C., Berdel, W.E. Serve, H. (2005) Signal transduction of oncogenic Flt3. International Journal of Hematology, 82, 93 99.
3. Kalo, M.S. Pasquale, E.B. (1999) Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry, 38, 14396 14408.
4. Kancha, R.K., Grundler, R., Peschel, C. Duyster, J. (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental Hematology, 35, 1522 1526.
5. Levis, M. Small, D. (2005) FLT3 tyrosine kinase inhibitors. International Journal of Hematology, 82, 100 107.
6. Mahboobi, S., Teller, S., Pongratz, H., Hufsky, H., Sellmer, A., Botzki, A., Uecker, A., Beckers, T., Baasner, S., Schächtele, C., Überall, F., Kassack, M.U., Dove, S. Böhmer, F.D. (2002) Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. Journal of Medicinal Chemistry, 45, 1002 1018.
7. Mahboobi, S., Uecker, A., Sellmer, A., Cenac, C., Hocher, H., Pongratz, H., Eichhorn, E., Hufsky, H., Trümpler, A., Sicker, M., Heidel, F., Fischer, T., Stocking, C., Elz, S., Böhmer, F.D. Dove, S. (2006) Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. Journal of Medicinal Chemistry, 49, 3101 3115.
8. O'Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich, M.C. Cherrington, J.M. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 101, 3597 3605.
9. Schmidt-Arras, D., Schwäble, J., Böhmer, F.D. Serve, H. (2004) Flt3 receptor tyrosine kinase as a drug target in leukemia. Current Pharmaceutical Design, 10, 1867 1883.
10. Schmidt-Arras, D.E., Böhmer, A., Markova, B., Choudhary, C., Serve, H. Böhmer, F.D. (2005) Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Molecular and Cellular Biology, 25, 3690 3703.
11. Stirewalt, D.L. Radich, J.P. (2003) The role of FLT3 in haematopoietic malignancies. Nature Reviews Cancer, 3, 650 665.
12. Teller, S., Kramer, D., Böhmer, S.A., Tse, K.F., Small, D., Mahboobi, S., Wallrapp, C., Beckers, T., Kratz-Albers, K., Schwäble, J., Serve, H. Böhmer, F.D. (2002) Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia, 16, 1528 1534.
13. Tickenbrock, L., Müller-Tidow, C., Berdel, W.E. Serve, H. (2006) Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opinion Emerging Drugs, 11, 153 165.
14. Waltenberger, J., Uecker, A., Kroll, J., Frank, H., Mayr, U., Bjorge, J.D., Fujita, D., Gazit, A., Hombach, V., Levitzki, A. Böhmer, F.D. (1999) A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circulation Research, 85, 12 22.